NCT07395687

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 333 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	UBT251	UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.
DRUG	Placebo	Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

Timeline

• Start date: 2026-02-02
• Primary completion: 2027-01-14
• Completion: 2027-02-18
• First posted: 2026-02-09
• Last updated: 2026-04-17

Locations

3 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study